dialogue with other companies ongoing A new $299 savings offer, available from July 1 July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers, a global leader in science-backed weight management, beginning July 1, 2025
Figure 1: Labial melanotic macule
With sublingual semaglutide, the medication is absorbed through the tissues under the tongue
doi: 10.3390/fermentation4030053 72 MorataA.LoiraI.VejaranoR.GonzlezC.CallejoM
Long operating history since 2017, with roughly $1.03 billion raised